We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Dr Patrick P DeLuca is emeritus professor and Sullivan Medallist at the University of Kentucky College of Pharmacy and former president of the American Association of Pharmaceutical Scientists.|Dr Heidi M Mansour is assistant professor of pharmaceutics and pharmaceutical technology at the University of Kentucky College of Pharmacy. She also holds an appointment at the UK Center of Membrane Sciences.
Dr Andreas Ohm is head of early development at Bayer HealthCare. Previously, following the merger of Bayer Pharma with Schering in 2008, he was appointed head of pharmaceutical technology of Bayer Schering Pharma.
Andreas Maack is head of corporate security for Merck. He joined Merck in 2010 and is responsible for governance issues and prevention measures in security, especially case and incident handling (counterfeiting and product-related crime).
Comparative effectiveness trials are becoming an ever-more important part of the R&D mix for pharmaceutical firms when it comes to drug development. Image: National Cancer Institute|Dorthe Lerche Berg is head of department, clinical supply coordination at H Lundbeck, with responsibility for managing clinical supply coordination, coordination of packaging activities, distribution and IVRS activities for clinical studies.
The PATH/WHO Optimize project aims to implement effective supply chain solutions in developing countries on a large scale by 2020. |John Lloyd is a senior technical advisor for PATH. He is currently working on the development and introduction of a software application to plan for future equipment needs in cold chain systems.
Jay Mehta is a senior analyst in healthcare practice at GBI Research. Prior to joining the company, he completed his MBA in international management from the Management Development Institute in Gurgaon, India.
China is expected to record double-digit growth in pharmaceutical consumer spending due to increased government and consumer expenditure.
Deal values increased in the second quarter of 2011, reaching $42.1bn compared with $27.6bn in Q1 2011, an increase of 52%.
Sheryl Coughlin’s expertise covers healthcare research, organisational strategy and performance management in private and public sector healthcare organisations. She has worked in Hong Kong, Singapore, Australia and the US.
Ranjith Gopinathan is programme manager, life sciences and healthcare practice at Frost & Sullivan. He has over seven years’ experience in international marketing, consulting and business research.